2017 Poland Cancer Diagnostics Market: Emerging Cancer Diagnostics, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains—Test Volume and Sales Forecasts, Competitive Strategies, Opportunities for Suppliers

March 2017 | 535 pages | ID: 28B71254327EN
Venture Planning Group

Abstracts

This new report from VPGMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

• Specific new product development opportunities with potentially significant market appeal during the next five years.
• Design criteria for new products.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.

Cancer Diagnostic Tests Analyzed in the Report--over 200 current and emerging assays, including Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines and Immunohistochemical Stains, such as:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Instrumentation Review

• Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

• Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.
• Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.
• Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

• Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Contains 535 pages and 70 tables

Contents

1. INTRODUCTION

2. MARKET OVERVIEW

3. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

4. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

5. ALTERNATIVE MARKET PENETRATION STRATEGIES

6. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

7. MAJOR CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS

  1. INTRODUCTION
  2. CANCER DIAGNOSTIC CLASSIFICATION
  3. ACTH
  4. ALPHA FETOPROTEIN (AFP)
  5. BETA 2 MICROGLOBULIN
  6. CA 15 3/27.29
  7. CA 199
  8. CA 125
  9. CALCITONIN
  10. CARCINOEMBRIONIC ANTIGEN (CEA)
  11. ESTROGEN AND PROGESTERONE RECEPTORS
  12. FERRITIN
  13. GASTRIN
  14. HUMAN CHORIONIC GONADOTROPIN (HCG)
  15. INSULIN
  16. NSE
  17. OCCULT BLOOD
  18. PAP SMEAR/HPV
  19. PROSTATIC ACID PHOSPHATASE (PAP)
  20. PROSTATE    SPECIFIC ANTIGEN (PSA)
  21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
  22. T AND B LYMPHOCYTES
  23. TDT
  24. THYROGLOBULIN
  25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
  26. BIOCHEMICAL CANCER DIAGNOSTICS
  27. ONCOGENES
  Abl/abl bcr
  AIB1
  BCL2
  BRCA1
  CD44
  C-fos
  C-myb
  C-myc
  CYP    17
  ErbB
  HPC1
  Nmyc
  P40
  P51
  P53
  PIK3CA
  PTI1
  Ras
  Reg
  Sis
  Src
  28. POLYPEPTIDE GROWTH FACTORS
  Basic Fibroblast Growth Factor
  Beta    TGF
  Cachectin (TNT)
  Calmodulin
  ECFR
  Nerve Growth Factor (NGF)
  Epidermal Growth Factor (EGF)
  Ornithine Decarboxylase
  Transferrin
  Transforming Growth Factor    Alpha
  29. ECTOPIC HORMONES
  30. COLONY STIMULATING FACTORS
  31. LYMPHOKINES
  Alpha    Interferon
  B Cell Growth Factors
  B Cell Growth Factor (BCGF)
  Gamma    Interferon
  Interleukin    1 (IL1)
  Macrophage Activating Factor
  32. IMMUNOHISTOCHEMICAL STAINS
  33. EMERGING CANCER DIAGNOSTICS
  NAcetylglucosamine
  Actin
  Alpha    Actin
  Antineuronal Antibodies
  7B2
  B72.3
  Bax
  BCD    F9
  BLCA 4
  Blood Group Antigens A, B, H
  CA
  CA 72    4/TAG    72
  CA
  CA 242
  CA 549
  CAM
  CAR    3
  Cathepsin    D
  Chromogranin A and B
  Cluster 1 Antigen
  Cluster    5/5A Antigen
  CTA
  CU18
  DR    70
  DU    AN2
  Endometrial Bleeding Associated Factor
  Endostatin
  Epithelial Membrane Antigen
  Feulgen Hydrolysis
  Fibronectin
  FSH
  (1    >3)    Lfucosyltransferase
  Gastrin    Releasing Peptide (GRP)
  GDCFP    15
  Glucagon
  Glycoamines
  H23
  Her    2
  Human Carcinoma Antigen
  HPA
  HSP27
  Intermediate Filaments
  Cytokeratins/CK18/Cyfra 21    1
  Desmin
  Gliofibrillary Acid Protein
  Neurofilaments
  Vimentin
  KA
  Kinases
  KP16D3
  LAI
  Leukocyte Common Antigen
  Lewis Antigens
  Lysophosphatidic Acid (LPA)
  Ma 695/Ma
  MABDF3
  MAG
  ME1
  Minactivin
  MN/CA9
  MSA
  Mucin Cancer Antigen (MCA)
  Multiple Tumor Suppressor
  Myosin
  NEA 130
  NMP22
  OA 519
  Opiod Peptides
  P    glycoprotein
  Pancreatic Oncofetal Antigen (POA)
  Placental Lactogen
  PR92
  Proliferative Index, Ki 67
  Px
  RB Inactivation/Deletion
  Ret
  SCCL
  Selectin
  Sialic Acid
  Sialyl SSEA 1/SLX
  SN10
  Somatostatin
  TA 90
  TABA
  Tachykinin
  TAG
  TPS
  Troponin
  Tubulin
  VCAM
  VEGF
  Villen

8. INSTRUMENTATION REVIEW AND MARKET NEEDS

9. CURRENT AND EMERGING TECHNOLOGIES

  1. MONOCLONAL AND POLYCLONAL ANTIBODIES
  2. IMMUNOASSAYS
  3. MOLECULAR DIAGNOSTICS
  4. CHROMOSOME ANALYSIS
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. ARTIFICIAL INTELLIGENCE
  6. FLOW CYTOMETRY
  7. TW DIMENSIONAL GEL ELECTROPHORESIS (2    DGE)
  8. BIOSENSORS
  9. COMPETING/COMPLEMENTING TECHNOLOGIES

10. MARKET SIZE, TEST VOLUME AND SALES FORECASTS

11. COMPETITIVE PROFILES

  Abbott
  AdnaGen/Alere
  Agilent Technologies
  Applied Gene Technologies
  Arca Biopharma
  Beckman Coulter/Danaher
  Becton Dickinson
  Biomedical Diagnostics
  bioMerieux
  Bio-Rad
  CellSearch
  Cepheid
  Correlogic Systems/Vermillion
  Decode Genetics
  Diadexus
  Diagnocure
  Diasorin
  Eiken Chemical
  Elitech Group
  Enterix
  Enzo Biochem
  Epigenomics
  Exact Sciences
  Fujirebio
  Guided Therapeutics
  Hologic/Genrobe
  Kreatech/Leica
  Kyowa Medex
  Mackay Life Sciences
  Myriad Genetics
  OncoLab
  Ortho    Clinical Diagnostics
  Panacea Pharmaceuticals
  Polartechnics
  Polymedco
  PreMD
  Qiagen
  Quest Diagnostics
  Radient Pharmaceuticals
  Roche
  Scienion
  Sequenom
  Siemens Healthcare
  Takara Bio
  Targeted Diagnostics & Therapeutics
  Tosoh
  Thermo Fisher/Affimetrix
  Veridex
  Wako Pure Chemicals
  Wallac/PE
  Zila

12. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS

List Of Tables

LIST OF TABLES

Cancer Diagnostic Test Volume and Sales Forecasts
Cancer Diagnostic Volume Forecast by Test
Cancer Diagnostics Sales Forecast by Test
ACTH Test Volume and Diagnostics Sales Forecast
AFP Test Volume and Diagnostics Sales Forecast
Beta    2 Microglobulin Test Volume and Diagnostics Sales Forecast
CA 15 3/27.29 Test Volume and Diagnostics Sales Forecast
CA 199 Test Volume and Diagnostics Sales Forecast
CA 125 Test Volume and Diagnostics Sales Forecast
Calcitonin Test Volume and Diagnostics Sales Forecast
Cathepsin Test Volume and Diagnostics Sales Forecast
CEA Test Volume and Diagnostics Sales Forecast
Chromogranin Test Volume and Diagnostics Sales Forecast
Colon    specific Antigen Test Volume and Diagnostics Sales Forecast
Cytokeratins Test Volume and Diagnostics Sales Forecast
Estrogen Receptor Test Volume and Diagnostics Sales Forecast
Ferritin Test Volume and Diagnostics Sales Forecast
Gastrin Test Volume and Diagnostics Sales Forecast
HCG Test Volume and Diagnostics Sales Forecast
Insulin Test Volume and Diagnostics Sales Forecast
Interferons Test Volume and Diagnostics Sales
Interleukins Test Volume and Diagnostics Sales Forecast
Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast
NSE Test Volume and Diagnostics Sales Forecast
Nucleolar Test Volume and Diagnostics Sales Forecast
Occult Blood Test Volume and Diagnostics Sales Forecast
Oncogenes Test Volume and Diagnostics Sales Forecast
Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast
PAP Smear Test Volume and Diagnostics Sales Forecast
Parathyroid Hormone Test Volume and Diagnostics Sales Forecast
Progesterone Receptor Test Volume and Diagnostics Sales Forecast
PAP Test Volume and Diagnostics Sales Forecast
PSA Test Volume and Diagnostics Sales Forecast
S    100 Protein Test Volume and Diagnostics Sales Forecast
Serotonin Test Volume and Diagnostics Sales Forecast
Sialic Acid Test Volume and Diagnostics Sales Forecast
Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast
TDT Test Volume and Diagnostics Sales Forecast
Thymidine Kinase Test Volume and Diagnostics Sales Forecast
Thyroglobulin Test Volume and Diagnostics Sales Forecast
TPA Test Volume and Diagnostics Sales Forecast
Cancer Diagnostic Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta    2 Microglobulin Tests
Major Companies Developing or Marketing CA 15 3/27.29 Tests
Major Companies Developing or Marketing CA 199 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications in Cancer Diagnosis
Oncogenes Potential Applications in Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications in Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications in Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis